Neurological disorders – including Parkinson’s – are leading source of disability globally
Author: Almaz OhenePublished: 16 November 2017
Prep: Cook: Serves:
New research published this week in the journal ‘JAMA Neurology’ by Professor Bastiaan Bloem, from Radboud University Nijmegen Medical Centre in the Netherlands, and Dr Ray Dorsey from University of Rochester Medical Center, shows that neurological disorders are now the leading source of disability worldwide
The medical community must mobilise to respond to the predicted rapid increase in people living with Parkinson’s over the next twenty years, argue leading Parkinson’s specialists Professor Bastiaan Bloem and Dr Ray Dorsey in a journal article this week.
In an article called ‘The Parkinson Pandemic – A Call to Action’ in the journal ‘JAMA Neurology’ earlier this week, the expert physicians point out that between 1990 and 2015, the prevalence of Parkinson’s more than doubled, with an estimated 6.9 million people worldwide living with the condition. They also estimate that by 2040, the number of people with Parkinson’s will increase to 14.2 million as the population ages.
In a bid to combat this growing pandemic, the authors argue that the medical community should pursue the same strategies that transformed HIV from an unknown and fatal illness, into a highly treatable chronic condition.
Dr Ray Dorsey, from the University of Rochester Medical Center, US, said: “Pandemics are usually equated with infectious diseases like Zika, influenza, and HIV – but neurological disorders are now the leading cause of disability in the world and the fastest growing is Parkinson’s disease.”
Their article echoes another study, the ‘Global Burden of Disease’, also co-authored by Dorsey, which appeared in ‘The Lancet Neurology’ in September. That study tracked the prevalence of neurological diseases such as Parkinson’s, Alzheimer’s, stroke, epilepsy, meningitis, encephalitis, multiple sclerosis, and migraine, both globally and by individual country.
Professor Bastiaan Bloem, of the Radboud University NijmegenMedical Centre, the Netherlands, said: “People with HIV infection simply demanded better treatments and successfully rallied for both awareness and new treatments, literally chaining themselves to the doors of pharmaceutical companies. Today, HIV has become a treatable, chronic disease. This upcoming increase in the number of Parkinson’s patients is striking, and frankly, worrisome. We feel it is urgent that people with Parkinson’s go to the pharmaceutical industry and policymakers alike, demanding immediate action to fight this enormous threat.”
Dr Dorsey continued: “For too long the Parkinson’s community has been too quiet on these issues. Building on the AIDS community’s motto of ‘silence equals death’, the Parkinson’s community should make their voices heard. The current and future burden of this debilitating disease depends upon their action.”
The two academics argue that access to care for Parkinson’s – a highly treatable condition – is also limited. In the US for example, more than 40% of individuals with Parkinson’s over the age of 65 do not see a neurologist, while an online survey of 35 European countries showed that 40% of respondents had never seen a Parkinson’s specialist. In less wealthy nations, many are never diagnosed. In a door-to-door study in Bolivia, none of the individuals found to have the condition had ever been diagnosed or received treatment.
Todd Sherer, CEO of The Michael J Fox Foundation, said: “Too many people have Parkinson’s today and more will face diagnoses tomorrow. We all – government, patient organisations, researchers, doctors and patients – must work together for better care for those living with this disease and research toward a future without Parkinson’s.”
Dr Ray Dorsey Dr Ray Dorsey is David M Levy professor of neurology and director of the Center for Health and Technology at the University of Rochester Medical Center, US, where he is helping investigate new treatments for movement disorders and improve the way care is delivered for people with Parkinson and other neurological disorders.
Dr Dorsey previously directed the movement disorders division and neurology telemedicine at Johns Hopkins, Maryland, US. Dr Dorsey’s research has been published in the leading medical, neurology, and economic journals and has been featured in The New York Times, and The Wall Street Journal.
Image credit: University of Rochester Medical Center
Professor Bastiaan Bloem Baastian Bloem is a consultant neurologist at the Department of Neurology, Radboud University Nijmegen Medical Centre, the Netherlands. In 1994, he obtained his PhD degree at the Leiden University Medical Centre, the Netherlands. In 2002, he founded and became medical director of the Parkinson Centre Nijmegen (ParC), the Netherlands, which was recognised from 2005 onwards as centre of excellence for Parkinson’s disease.
Together with Dr Marten Munneke, he also developed ParkinsonNet, where people with Parkinson’s “co-design” their treatment programme in collaboration with a dedicated, multi-disciplinary team – accessed via ParkinsonNet’s online database of expert practitioners.
Download the Parkinson’s app endorsed by José Mourinho
i-PROGNOSIS helps Parkinson's outcomes via patient data logging
7 days ago
New insights on immune cell process and Parkinson’s disease
Insoluble clumps of the protein alpha-synuclein, which can cause damage to brain cells, have been previously linked to Parkinson’s. Now, scientists in Germany, France and the US have uncovered new details on how brain cells respond to these clusters. The researchers discovered that the brain’s immune cells may be able to join together to break down the protein clumps. According to a press release, this was previously unknown. They also found that these neighbouring cells share mitochondria – structures that generate energy for chemical reactions – to help one another. In certain mutations associated with Parkinson’s, this process may be impaired. The researchers hope this insight could inform the development of new therapies. “We have opened the door to a field that will certainly engage researchers for many years to come,” said Professor Dr Michael Heneka, director of the Department of Neurodegenerative Diseases and Geriatric Psychiatry at the University Hospital…
Could analysing skin oil help diagnose Parkinson’s disease?
Parkinson’s disease patients tend to have high levels of oil, known as sebum, on their skin’s surface. Now, a study has suggested that analysing this substance may help when diagnosing the condition. The study revealed that sebum contains significant amounts of genetic material, specifically the molecule ribonucleic acid (RNA). Analysis of RNA contained in sebum – that is, skin surface lipids RNA, or SSL-RNA – could offer insights into a person’s health. Researchers in Japan examined SSL-RNA in men and women with and without Parkinson’s. The results suggested that the SSL-RNA profiles of those with Parkinson’s had “different characteristics” than those without. The researchers then tested whether examining these profiles with machine learning could reveal those who had Parkinson’s – and who didn’t. The team’s algorithm indicated a “relatively robust discriminatory ability,” supporting the further use of SSL-RNA as part of a future “non-invasive” method for diagnosis.
‘Sonic hedgehog’ protein could impact Parkinson’s disease dyskinesia
Dyskinesia is often caused by extended use of the common Parkinson’s medication levodopa – and can be debilitating for those with the condition. Now, researchers in the US may have found a way to suppress these involuntary movements through a protein called ‘sonic hedgehog’. To conduct their study, the team administered levodopa and sonic hedgehog agonists to rodent and non-human primate models of the condition. The results revealed that dopamine neurons use the protein to communicate with other neurons thought to play a role in levodopa-induced dyskinesia. Increased signalling of sonic hedgehog pathways was found to reduce this dyskinesia – providing “novel insight” into its formation and a “potential therapeutic solution”. “What we find,” wrote corresponding study author Professor Andreas Kottmann, “is that in several animal models, by replacing … dopamine together with agonists that mimic the effects of sonic hedgehog, these dyskinesias can be very much suppressed.”